Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening. Issue 5 (9th March 2016)

• Record Type: Journal Article
• Authors: Chen, Can; Deng, Jingjing; Yu, Xiaoping; Wu, Fengbo; Men, Ke; Yang, Qian; Zhu, Yanfeng; Liu, Xiaogang; Jiang, Qinglin
• Is Part Of: Molecular bioSystems. Volume 12:Issue 5(2016:May)
• Page Start: 1540
• Page End: 1551
• Publication Date: 2016-03-09
• Subjects: Molecular biology -- Periodicals; Biochemistry -- Periodicals; 571.7405
• DOI: 10.1039/c5mb00911a
• Languages: English
• ISSNs: 1742-206X

Abstract

Abstract : This study reveals DDR1 plays an important role in idiopathic pulmonary fibrosis and identifies a DDR1 inhibitor for possible future therapy. Abstract : Idiopathic pulmonary fibrosis (IPF) is a kind of a chronic and fatal lung disease leading to progressive lung function decline. Although several RNA microarray studies on IPF patients have been reported, their results were merely specific to each study with distinct platforms or sample types. In the current study, an integrative transcriptome meta-analysis of IPF was performed to explore regulated pathways, based on four independent expression profiling microarrays of IPF datasets, including 73 samples from IPF tissues or lung fibroblast cells. The results suggested the discoidin domain receptor 1 (DDR1) and downstream c-Jun N-terminal kinases (JNK) pathway may play important roles in the progression of IPF. To our knowledge, discoidin domain receptor 1 (DDR1) is a kind of receptor tyrosine kinase (RTK) with a unique ability to bind both fibrillar and non-fibrillar collagens. Based on the crystallographic structures of DDR1, the combination of molecular dynamics simulation and a hybrid protocol of a virtual screening method, comprised of PBVS (multicomplex-pharmacophore based virtual screening) and DBVS (docking based virtual screening) methods were used for retrieving novel DDR1 inhibitors from the SPECS database. Twelve hit compounds were selected from the hit compounds and shifted to experimental validations, and the most potent compound was evaluated for its anti-IPF capacity on murine IPF models. Thus, these results may provide valuable information for further discovery of potential lead compounds for IPF therapy.